Exploring the therapeutic effect of human recombinant IL11 on lesioned OA human osteochondral explants
Authors' conclusion
The current study showed that treatment of OA articular cartilage with hrIL11 is unlikely to be beneficial despite previous indications of hrIL11 as potential druggable target.
Study context
- Population
- Patients with OA; macroscopically preserved and lesioned OA articular cartilageRNA-sequencing dataset
- Participants
- 35 patients
- Comparison
- hrIL11 200ng/ml vs no hrIL11 in OA osteochondral explants
- Outcome
- Effects of hrIL11 on chondrocyte phenotype and Mankin scores in ex vivo OA articular cartilage
- Follow-up
- Two weeks
Methodological detailsRNA-sequencing co-expression analysis, ex vivo aged human osteochondral explant model
- RNA-sequencing co-expression analysis
- Ex vivo aged human osteochondral explant model
Main finding
As reported in the abstract
two weeks
- Overall unbeneficial effects on chondrocyte phenotype with hrIL11: upregulation of MMP13, EPAS1, RUNX2 and POSTN
- No significant differences in Mankin scores upon addition of hrIL11
Original publication
Exploring the therapeutic effect of human recombinant IL11 on lesioned OA human osteochondral explants. Arthritis Res Ther. Published 24 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →